Patient Guide: JS207 Combination Therapy in Triple-negative Breast Cancer

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 16 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07045311
Status: 🟢 Enrolling Now
Condition: Triple-negative Breast Cancer
Phase: PHASE2

Where You Can Participate

This study is available at 16 locations across the country.

Top locations include:
  • • Beijing, Beijing Municipality
  • • Beijing, Beijing Municipality
  • • Baoding, Hebei
  • • And 13 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

JS207 Combination Therapy in Triple-negative Breast Cancer - Join Clinical Trial NCTNCT07045311

How to Join This Clinical Trial - NCTNCT07045311

Learn how to participate in this PHASE2 trial studying an investigational therapy for Triple-negative Breast Cancer. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Triple-negative Breast Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Triple-negative Breast Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07045311 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 16 locations. Find a study site near you:

Clinical Research Site

Beijing, Beijing Municipality 100044 - China

Status: NOT_YET_RECRUITING

Clinical Research Site

Beijing, Beijing Municipality 100071 - China

Status: RECRUITING

Clinical Research Site

Baoding, Hebei 071030 - China

Status: RECRUITING

Clinical Research Site

Zhangzhou, Henan 450003 - China

Status: RECRUITING

Clinical Research Site

Wuhan, Hubei 430079 - China

Status: RECRUITING

Clinical Research Site

Nanjing, Jiangsu 210009 - China

Status: RECRUITING

Clinical Research Site

Nanjing, Jiangsu 210029 - China

Status: NOT_YET_RECRUITING

Clinical Research Site

Changchun, Jilin 130021 - China

Status: RECRUITING

Clinical Research Site

Dalian, Liaoning 116027 - China

Status: RECRUITING

Clinical Research Site

Shenyang, Liaoning 110002 - China

Status: RECRUITING

And 6 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Triple-negative Breast Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships